- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Study Finds Most Expensive of Eye Treatment Options Is Most Effective
Study finds that Regeneron Pharmaceuticals' more expensive Eylea help patients with severe eye disease caused by diabetes more than the less-expensive options from Roche Holding.
Regeneron Pharmaceuticals Inc.’s injection Eylea helped patients with severe eye disease caused by diabetes more than 2 Roche Holding AG medicines in the first head-to-head study of the drugs.
The finding may lead to doctors shifting more patients with diabetic macular edema to more-expensive Eylea, a boost for Regeneron since the drug generates about two-thirds of the company’s sales. Eylea performed significantly better than the Roche drugs in people with moderate to severe vision loss, making it the preferred choice, said Daniel Martin, chairman of the Cleveland Clinic’s Cole Eye Institute.
Read more at Bloomberg: http://bloom.bg/1DFfWf8
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
